Novartis announced the mutual agreement with Aurobindo Pharma USA to terminate the agreement to sell the Sandoz US generic oral solids and dermatology businesses to Aurobindo Pharma USA. This decision was taken as approval from the US Federal Trade Commission for the transaction was not obtained within anticipated timelines.
Sandoz will continue to operate its oral solids and dermatology business as part of the Sandoz US business.
